China Multiplex Assays Market (2026-2031)
The China Multiplex Assays Market was valued at $333.6 Million in 2026 and projected to reach to $561.5 Million by 2031, representing a compound annual growth rate of 11.0%. China's multiplex assays market is positioned for sustained growth through 2031, with the market expanding from USD 333.6 million in 2026 to USD 561.5 million by 2031.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Multiplex Assays Market Trends and Insights
- This 11.0% compound annual growth rate reflects China's accelerating adoption of advanced diagnostic technologies driven by rising healthcare spending, increasing disease prevalence, and government initiatives to modernize clinical laboratory infrastructure.
- China's position as a manufacturing hub and growing domestic demand for high-throughput diagnostic solutions are key catalysts propelling market growth. The multiplex assays sector in China benefits from expanding pharmaceutical and biotechnology research activities, coupled with heightened focus on precision medicine and personalized healthcare.
- China's regulatory environment has become increasingly supportive of innovative diagnostic platforms, enabling faster market entry for multiplex assay technologies.
- Between 2026 and 2031, China is expected to capture significant market share within the Asia Pacific region, driven by urbanization, improved healthcare access, and rising awareness of early disease detection among both healthcare providers and patients..
Key Market Statistics
- CAGR (2026-2031) 11.0% CAGR
- Market Size, 2026 ~USD 333.6 Million
- Forecast, 2031 ~USD 561.5 Million
- Country China
China Multiplex Assays Market Overview
Rapid Market Expansion :
China's multiplex assays market is growing at 11% CAGR, significantly outpacing the global rate of 8.3%, driven by increased healthcare investments and modernization of diagnostic infrastructure across urban and emerging markets.
Government Healthcare Initiatives :
China's commitment to upgrading clinical laboratory capabilities and expanding healthcare access in rural regions is accelerating adoption of multiplex assay technologies, supported by favorable regulatory policies and reimbursement frameworks.
Rising Disease Prevalence :
Increasing incidence of chronic diseases, infectious diseases, and cancer in China is driving demand for advanced diagnostic solutions that enable simultaneous detection of multiple biomarkers, improving clinical efficiency and patient outcomes.
Growing Healthcare Expenditure :
China's healthcare spending is expanding rapidly, with hospitals and diagnostic centers investing in multiplex assay platforms to enhance laboratory throughput, reduce testing costs per patient, and meet rising demand for comprehensive diagnostic testing.
China Multiplex Assays Market Dynamics
- This trajectory reflects structural shifts in China's healthcare system toward precision diagnostics and preventive medicine.
- Government initiatives promoting laboratory modernization, coupled with rising healthcare spending and increasing disease burden, create favorable conditions for market expansion. Key growth drivers include adoption of multiplex technologies in infectious disease screening, oncology diagnostics, and immunology testing across major hospitals and diagnostic centers.
- The competitive landscape is intensifying as both domestic and international manufacturers expand their presence in China, driving innovation and price optimization.
- Strategic partnerships between healthcare providers and diagnostic companies will further accelerate market penetration in tier-2 and tier-3 cities..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- China's multiplex assays market is valued at USD 333.6 million in 2026 and will grow to USD 561.5 million by 2031, representing an 11.0% CAGR.
- China's market growth outpaces the global average of 8.3%, driven by rising healthcare investments and modernization of diagnostic infrastructure.
- Government support for precision medicine and biotechnology innovation is accelerating multiplex assay adoption across China's clinical and research laboratories.
- China's manufacturing capabilities and large patient population position it as a critical growth engine for the Asia Pacific multiplex assays market.
Multiplex Assays Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | NEXT-GENERATION SEQUENCING (NGS) (Technology) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 8.3% from 2026 to 2031 |
| Largest Segment | CONSUMABLES (Product & Service) |
| Market Size Base Year (Billions) | ~USD 7.15 (2026) |
| Revenue Forecast (Billions) | ~USD 10.65 (2031) |
| Segments Covered | Product & Service, Type, Technology, Application, End User |
China Multiplex Assays Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Software & Services
By Type
- Autoimmune Diseases
- Bead-Based Nucleic Acid Assays
- Bead-Based Protein Assays
- Biomarker Discovery & Validation
- Cancer
- Cardiovascular Diseases
- Cell-Based Multiplex Assays
- Drug Discovery & Development
- Infectious Diseases
- Metabolism & Endocrinology Disorders
- Nervous System Disorders
- Nucleic Acid Multiplex Assays
- Other Diseases
- Other Nucleic Acid Assays
- Other Protein Assays
- Planar Nucleic Acid Assays
- Planar Protein Assays
- Protein Multiplex Assays
By Technology
- Flow Cytometry
- Fluorescence Detection
- Luminescence
- Multiplex Real-Time Pcr
- Next-Generation Sequencing (Ngs)
- Other Technologies
By Application
- Clinical Diagnostics
- Research & Development
By End User
- Academic & Research Institutes
- Contract Research Organizations
- Hospitals & Diagnostic Laboratories
- Other End Users
- Pharmaceutical & Biotechnology Companies
CHINA: MULTIPLEX ASSAY MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 100.1 | 109.1 | 119.2 | 130.5 | 143.1 | 157.2 | 173.1 | 191.1 | 9.9 |
| CONTRACT RESEARCH ORGANIZATIONS | 35.3 | 38.6 | 42.4 | 46.5 | 51.1 | 56.4 | 62.2 | 68.9 | 10.2 |
| HOSPITALS & DIAGNOSTIC LABORATORIES | 116.5 | 129.1 | 143.3 | 159.4 | 177.6 | 198.4 | 221.9 | 248.9 | 11.7 |
| OTHER END USERS | 21.4 | 23.2 | 25.1 | 27.3 | 29.7 | 32.4 | 35.3 | 38.7 | 9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 140.2 | 154.5 | 170.7 | 188.8 | 209.2 | 232.2 | 258.3 | 287.9 | 11 |
| TOTAL | 413.6 | 454.5 | 500.7 | 552.5 | 610.6 | 676.6 | 750.9 | 835.4 | 10.8 |
Target Audience
- Diagnostic Equipment Manufacturers : Need China-specific market data to assess market size, growth potential, and competitive positioning for multiplex assay platforms, guiding product development, pricing strategies, and distribution channel decisions in this high-growth market.
- Healthcare Providers & Hospital Networks : Require market insights to evaluate multiplex assay adoption trends, technology ROI, and procurement benchmarks across Chinese hospitals, supporting capital equipment decisions and laboratory modernization initiatives.
- In Vitro Diagnostics (IVD) Companies : Need comprehensive China market analysis to identify growth opportunities, understand regulatory pathways, assess reimbursement scenarios, and develop market entry or expansion strategies for multiplex assay products.
- Private Equity & Investment Firms : Require validated market sizing and growth forecasts for China to evaluate investment opportunities in diagnostic companies, assess portfolio company growth potential, and support M&A decision-making in the healthcare diagnostics sector.
- Healthcare Consultants & Strategy Advisors : Need China-specific multiplex assays market data to support client advisory projects, competitive benchmarking, market entry strategies, and long-term healthcare industry forecasting for multinational and domestic healthcare organizations.
Key Companies in the China Multiplex Assays Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug product services (oral solid, sterile, specialty dosage),Pharmaceutical development services (early to late-stage),Drug substance services (small-molecule and biologics APIs), |
| NANOSTRING TECHNOLOGIES, INC | United States | Private Company | nCounter instruments (Pro, FLEX, SPRINT),nCounter consumables, CodeSets, and panels,GeoMx DSP systems, |
| BIOCARTIS SA | Belgium | Private Company | Idylla oncology assays (cartridges),Idylla infectious disease assays,Idylla instruments and accessories, |
| IMMUCOR, INC. | United States | Private Company | Transfusion (serology instruments and reagents),Transplant & Molecular (HLA, HPA, HEA assays and systems),Platelet-focused and specialty coagulation products, |
| MAXCYTE, INC | United States | Public Company | ExPERT ATx instruments and related consumables,ExPERT STx instruments and related consumables,ExPERT GTx instruments and related consumables, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Arrays and array consumables, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics – infectious and gastrointestinal diseases,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX assays, |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (VITEK, culture media, BACT/ALERT, VIDAS, ETEST, API),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Industrial applications (GENE-UP, VERIFLOW, BIOBALL, TEMPO, ENDONEXT, CHEMUNEX), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, catheters, sharps, basic disposables),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, related solutions), |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual/reproductive health assays, |
| MERCK KGAA | Germany | Public Company | Life Science (tools, reagents, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, delivery equipment), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| QUANTERIX CORPORATION | United States | Public Company | HD-X instruments and related assays,SR-X and SP-X instruments and assays,Assay kits, reagents, and antibodies (standalone sales), |
| BIO-TECHNE CORPORATION | United States | Public Company | Protein Sciences (reagents and proteomic tools),Diagnostics and Spatial Biology, |
| SEEGENE INC. | South Korea | Public Company | Respiratory disease detection panels,Gastrointestinal and STI pathogen panels,HPV, TB, and drug-resistance assays, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the life sciences sector.
NANOSTRING TECHNOLOGIES, INC
NanoString Technologies, Inc. is a United States-based private company founded in 2003 with 550 employees focused on life science research tools.
BIOCARTIS SA
Biocartis SA is a Belgian private company founded in 2014 with 500 employees developing molecular diagnostics solutions.
IMMUCOR, INC.
Immucor, Inc. is a United States-based private company founded in 1982 with 1,125 employees providing immunohematology and transfusion diagnostics solutions.
MAXCYTE, INC
MaxCyte, Inc. is a United States-based public company founded in 1998 with 91 employees developing cell engineering technologies.
ILLUMINA, INC.
Illumina, Inc. is a United States-based public company founded in 1998 with 8,625 employees specializing in DNA sequencing and genetic analysis technologies.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a United States-based public company founded in 1952 with 7,450 employees manufacturing life science research and clinical diagnostics products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and services globally.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees specializing in in vitro diagnostics.
BIOMéRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees developing in vitro diagnostics and microbiology solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees manufacturing medical devices and diagnostics.
QIAGEN N.V.
QIAGEN N.V. is a Netherlands-based public company founded in 1984 with 5,500 employees providing molecular diagnostics and life science research tools.
MERCK KGAA
Merck KGaA is a German public company founded in 1668 with 59,077 employees operating in pharmaceuticals, life sciences, and performance materials.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees operating diversified businesses including diagnostics and life sciences.
QUANTERIX CORPORATION
Quanterix Corporation is a United States-based public company founded in 2007 with 450 employees developing ultra-sensitive protein detection technologies.
BIO-TECHNE CORPORATION
Bio-Techne Corporation is a United States-based public company founded in 1976 with 3,100 employees providing life science tools and reagents.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees specializing in molecular diagnostics and PCR-based testing solutions.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation for China (USD 333.6M in 2026) and verified 5-year forecast (USD 561.5M by 2031) to support investment decisions, business planning, and competitive positioning in this high-growth market.
- China-Specific Growth Drivers : Understand unique factors accelerating China's 11% CAGR—government healthcare initiatives, rising disease prevalence, and healthcare spending patterns—to identify market entry opportunities and tailor product strategies for Chinese healthcare providers.
- Competitive Landscape Intelligence : Gain insights into China's competitive dynamics, including domestic vs. international player positioning, regulatory environment, and reimbursement trends essential for market penetration and partnership strategies.
- Regional Expansion Strategy : Leverage detailed China market analysis to prioritize geographic expansion across tier-1, tier-2, and tier-3 cities, identify high-potential hospital networks, and develop localized go-to-market strategies.
- Risk Mitigation & Forecasting : Access comprehensive China market data to assess regulatory risks, reimbursement changes, and competitive threats, enabling informed decision-making and long-term strategic planning in this critical Asian market.
Frequently asked questions
What is the current size of China's multiplex assays market?
China's multiplex assays market is valued at USD 333.6 million in 2026 and is projected to reach USD 561.5 million by 2031.
What is the growth rate of China's multiplex assays market?
China's multiplex assays market is growing at a compound annual growth rate (CAGR) of 11.0% from 2026 to 2031.
How does China's multiplex assays market compare to global growth?
China's market growth rate of 11.0% significantly exceeds the global CAGR of 8.3%, indicating faster adoption and expansion in China.
What factors are driving growth in China's multiplex assays market?
Key drivers include rising healthcare spending, government support for precision medicine, modernization of laboratory infrastructure, and increasing disease prevalence in China.
What is the forecast size of China's multiplex assays market by 2031?
China's multiplex assays market is forecasted to reach USD 561.5 million by 2031, representing significant expansion from the 2026 baseline.
RESEARCH METHODOLOGY
The objective of this study is to analyze key market dynamics, including drivers, opportunities, restraints, and challenges, as well as the strategies of major players. It aims to monitor developments across leading players, including acquisitions, product launches, expansions, agreements, and partnerships. Additionally, the study will examine the competitive landscape of the multiplex assay market by evaluating market participants based on various criteria within the overarching categories of business and product strategy. To estimate the market size, both top-down and bottom-up approaches were employed. The market breakdown and data triangulation methods were used to assess segment and subsegment sizes.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were primarily industry experts from core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. The tiers are as follows: Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
For the global market value, annual revenue figures were calculated using revenue mapping for major product manufacturers and OEMs active in the global multiplex assay market. All major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. Also, the global multiplex assay market was split into various segments and sub-segments:
- List of major players operating in the products market at the regional and/or country level
- Product mapping of various multiplex assay manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from multiplex assay (or the nearest reported business unit/product category)
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global multiplex assay market
The data mentioned above was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
Market Size Estimation (Bottom-up & Top-down Approaches)
Data Triangulation
After determining the overall size of the global multiplex assay market using the methodology described above, the market was segmented into several segments and subsegments. The data triangulation and market breakdown procedures were employed, as applicable, to complete the overall market engineering process and obtain exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand- and supply-side participants.
Market Definition
The multiplex assay market comprises analytical testing platforms that enable the qualitative and quantitative assessment of multiple analytes from a single biological sample in a single run. These platforms offer advantages such as reduced testing time, increased automation, and the need for fewer biological samples compared to singleplex assays. The industry encompasses instrumentation, reagents, software, and other services utilized for a wide range of applications globally.
Key Stakeholders
- Manufacturers of multiplex assay products
- Suppliers and distributors of multiplex assay products
- Hospitals
- Diagnostic, clinical, and research laboratories
- Research & development (R&D) companies
- Group purchasing organizations (GPOs)
- Medical research laboratories
- Academic medical centers and universities
- Corporate entities
- Accountable care organizations (ACOs)
- Community centers
- Government institutes
- Market research and consulting firms
- Contract manufacturing organizations (CMOs)
- Contract research organizations (CROs)
- Venture capitalists and investors
Report Objectives
- To define, describe, segment, and forecast the multiplex assay market by product & service, type, technology, application, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiplex assay market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the multiplex assay market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the multiplex assay market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the multiplex assay market
- To benchmark players within the multiplex assay market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Available customizations:
Based on the given market data, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
- Further breakdown of the Rest of Europe multiplex assay market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the Rest of Asia Pacific multiplex assay market into South Korea, Taiwan, and others
- Further breakdown of the Rest of Latin America multiplex assay market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Southeast Asia multiplex assay market into Malaysia, Singapore, Australia, New Zealand, and others
COMPETITIVE LANDSCAPE ASSESSMENT
- Market Share Analysis, by region (North America and Europe), which provides the market share of the top 3 to 5 key players in the multiplex assay market
- Competitive leadership mapping for established players in the US
Get the Full Multiplex Assays Market Report
Full forecast, segment splits, and company analysis for all Multiplex Assays Market.
- Canada Multiplex Assays Market
- US Multiplex Assays Market
- Germany Multiplex Assays Market
- UK Multiplex Assays Market
- France Multiplex Assays Market
- Italy Multiplex Assays Market
- Spain Multiplex Assays Market
- Japan Multiplex Assays Market
- India Multiplex Assays Market
- Brazil Multiplex Assays Market
- Mexico Multiplex Assays Market
- Rest Of Europe Multiplex Assays Market
- Rest Of Asia Pacific Multiplex Assays Market
- Rest Of Latin America Multiplex Assays Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report